Biodexa Pharmaceuticals PLC
BDRX2.270USD
-0.030-1.30%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
14.06BMarket Cap
13.02P/E TTM
More Details of Biodexa Pharmaceuticals PLC Company
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Biodexa Pharmaceuticals PLC Info
Ticker SymbolBDRX
Company nameBiodexa Pharmaceuticals PLC
IPO dateDec 08, 2014
CEOStamp (Stephen A)
Number of employees- -
Security typeDepository Receipt
Fiscal year-endDec 08
Address1 Caspian Point
CityABINGDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeCF10 4DQ
Phone4401235888300
Websitehttps://www.biodexapharma.com/
Ticker SymbolBDRX
IPO dateDec 08, 2014
CEOStamp (Stephen A)
Company Executives of Biodexa Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Belgium
381.00K
100.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 29
Updated: Sat, Nov 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Brio Capital Management LLC
2.71%
UBS Switzerland AG
1.12%
Abbe (Richard)
0.39%
Bukwang Pharmaceutical Co., Ltd.
0.23%
Melior Pharmaceuticals I, Inc.
0.23%
Other
95.32%
Shareholders
Shareholders
Proportion
Brio Capital Management LLC
2.71%
UBS Switzerland AG
1.12%
Abbe (Richard)
0.39%
Bukwang Pharmaceutical Co., Ltd.
0.23%
Melior Pharmaceuticals I, Inc.
0.23%
Other
95.32%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
2.92%
Bank and Trust
1.12%
Corporation
0.56%
Individual Investor
0.39%
Investment Advisor
0.23%
Hedge Fund
0.07%
Research Firm
0.02%
Other
94.69%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
25
26.99K
4.36%
-3.65K
2025Q3
27
27.63K
4.95%
+6.43K
2025Q2
30
21.20K
5.92%
-17.70K
2025Q1
32
21.37K
16.41%
+10.40K
2024Q4
31
19.96K
16.99%
+9.20K
2024Q3
33
10.76K
4.86%
+5.02K
2024Q2
29
4.42K
2.68%
+1.32K
2024Q1
25
3.10K
2.07%
+2.75K
2023Q4
26
3.28K
0.82%
+3.22K
2023Q3
18
57.00
107.67%
+15.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Brio Capital Management LLC
16.77K
2.71%
+11.06K
+193.61%
Nov 14, 2024
UBS Switzerland AG
6.92K
1.12%
+6.73K
+3379.90%
Sep 30, 2025
Abbe (Richard)
2.43K
0.39%
+2.43K
--
Jul 19, 2024
Bukwang Pharmaceutical Co., Ltd.
1.42K
0.23%
+1.42K
--
Apr 01, 2024
Melior Pharmaceuticals I, Inc.
1.42K
0.23%
+1.42K
--
Apr 01, 2024
Mercer Street Capital Partners, LLC
1.42K
0.23%
+793.00
+126.88%
Apr 01, 2024
GAMMA Investing LLC
1.35K
0.22%
+158.00
+13.23%
Sep 30, 2025
GS Capital Partners LLC
631.00
0.1%
+631.00
--
Apr 01, 2024
District 2 Capital LP
403.00
0.07%
-449.00
-52.70%
Nov 11, 2024
SBI Securities Co., Ltd.
115.00
0.02%
-452.00
-79.72%
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Date
Type
Ratio
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Mar 16, 2023
Merger
4→1
View more
FAQs
Who are the top five shareholders of Biodexa Pharmaceuticals PLC?
The top five shareholders of Biodexa Pharmaceuticals PLC are:
Brio Capital Management LLC holds 16.77K shares, accounting for 2.71% of the total shares.
UBS Switzerland AG holds 6.92K shares, accounting for 1.12% of the total shares.
Abbe (Richard) holds 2.43K shares, accounting for 0.39% of the total shares.
Bukwang Pharmaceutical Co., Ltd. holds 1.42K shares, accounting for 0.23% of the total shares.
Melior Pharmaceuticals I, Inc. holds 1.42K shares, accounting for 0.23% of the total shares.
Brio Capital Management LLC holds 16.77K shares, accounting for 2.71% of the total shares.
UBS Switzerland AG holds 6.92K shares, accounting for 1.12% of the total shares.
Abbe (Richard) holds 2.43K shares, accounting for 0.39% of the total shares.
Bukwang Pharmaceutical Co., Ltd. holds 1.42K shares, accounting for 0.23% of the total shares.
Melior Pharmaceuticals I, Inc. holds 1.42K shares, accounting for 0.23% of the total shares.
What are the top three shareholder types of Biodexa Pharmaceuticals PLC?
The top three shareholder types of Biodexa Pharmaceuticals PLC are:
Brio Capital Management LLC
UBS Switzerland AG
Abbe (Richard)
Brio Capital Management LLC
UBS Switzerland AG
Abbe (Richard)
How many institutions hold shares of Biodexa Pharmaceuticals PLC (BDRX)?
As of 2025Q4, 25 institutions hold shares of Biodexa Pharmaceuticals PLC, with a combined market value of approximately 26.99K, accounting for 4.36% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.59%.
What is the biggest source of revenue for Biodexa Pharmaceuticals PLC?
In FY2023, the -- business generated the highest revenue for Biodexa Pharmaceuticals PLC, amounting to -- and accounting for --% of total revenue.
